摘要:
The present invention has an object to provide a means to effectively enhance the production of cytokines and/or chemokines in mammals. The object is solved by providing an agent for enhancing the production of cytokines and/or chemokines, which comprises, as an effective ingredient, a polypeptide having any one of the amino acid sequences of SEQ ID NOs:1 to 3; a polypeptide having any one of the amino acid sequences of SEQ ID NOs:1 to 3, where one or more amino acids thereof are deleted or replaced with other amino acid(s) and/or one or more amino acids are added thereunto, without substantially losing the biological activity of the polypeptide.
摘要翻译:本发明的目的是提供有效增强哺乳动物中细胞因子和/或趋化因子的产生的方法。 通过提供用于增强细胞因子和/或趋化因子的产生的试剂来解决该问题,所述试剂包含作为有效成分的具有SEQ ID NO:1至3的任一氨基酸序列的多肽; 具有SEQ ID NO:1至3的任何一个氨基酸序列的多肽,其中一个或多个氨基酸被缺失或被其它氨基酸和/或一个或多个氨基酸所取代,而没有 基本上丧失了多肽的生物活性。
摘要:
The present invention has an object to provide a means to effectively enhance the production of cytokines and/or chemokines in mammals. The object is solved by providing an agent for enhancing the production of cytokines and/or chemokines, which comprises, as an effective ingredient, a polypeptide having any one of the amino acid sequences of SEQ ID NOs:1 to 3; a polypeptide having any one of the amino acid sequences of SEQ ID NOs:1 to 3, where one or more amino acids thereof are deleted or replaced with other amino acid(s) and/or one or more amino acids are added thereunto, without substantially losing the biological activity of the polypeptide.
摘要翻译:本发明的目的是提供有效增强哺乳动物中细胞因子和/或趋化因子的产生的方法。 通过提供用于增强细胞因子和/或趋化因子的产生的试剂来解决该问题,所述试剂包含作为有效成分的具有SEQ ID NO:1至3的任一氨基酸序列的多肽; 具有SEQ ID NO:1至3的任何一个氨基酸序列的多肽,其中一个或多个氨基酸被缺失或被其它氨基酸和/或一个或多个氨基酸加入,而没有 基本上丧失了多肽的生物活性。
摘要:
The present invention has an object to provide a tumor necrosis factor mutant protein, particularly, a tumor necrosis factor mutant protein specific to TNF-R1 or TNF-R2; tumor necrosis factor inhibitor; or tumor necrosis factor preparation containing it as an effective ingredient, and the object is solved by providing a tumor necrosis factor mutant protein where one or more amino acid residues selected from the group consisting of 29th, 31st, 32nd, 145th, 146th and 147th, or the group consisting of 84th to 89th from the N-terminal of the amino acid sequence of SEQ ID NO:1 is/are replaced with other amino acid residue(s); a tumor necrosis factor inhibitor; and a tumor necrosis factor preparation containing it as an effective ingredient.
摘要翻译:本发明的目的是提供肿瘤坏死因子突变蛋白,特别是TNF-R1或TNF-R2特异的肿瘤坏死因子突变体蛋白; 肿瘤坏死因子抑制剂; 或含有其作为有效成分的肿瘤坏死因子制剂,其目的是通过提供一种或多种选自第29,31,32,35,146和147位的氨基酸残基的肿瘤坏死因子突变蛋白来解决, 或由SEQ ID NO:1的氨基酸序列的N末端第84位至第89位的基团被其它氨基酸残基取代; 肿瘤坏死因子抑制剂; 和含有它作为有效成分的肿瘤坏死因子制剂。
摘要:
The present invention has an object to provide a tumor necrosis factor mutant protein, particularly, a tumor necrosis factor mutant protein specific to TNF-R1 or TNF-R2; tumor necrosis factor inhibitor; or tumor necrosis factor preparation containing it as an effective ingredient, and the object is solved by providing a tumor necrosis factor mutant protein where one or more amino acid residues selected from the group consisting of 29th, 31st, 32nd, 145th, 146th and 147th, or the group consisting of 84th to 89th from the N-terminal of the amino acid sequence of SEQ ID NO:1 is/are replaced with other amino acid residue(s); a tumor necrosis factor inhibitor; and a tumor necrosis factor preparation containing it as an effective ingredient.
摘要翻译:本发明的目的是提供肿瘤坏死因子突变蛋白,特别是TNF-R1或TNF-R2特异的肿瘤坏死因子突变体蛋白; 肿瘤坏死因子抑制剂; 或含有其作为有效成分的肿瘤坏死因子制剂,其目的是通过提供一种或多种选自第29,31,32,35,146和147位的氨基酸残基的肿瘤坏死因子突变蛋白来解决, 或由SEQ ID NO:1的氨基酸序列的N末端第84位至第89位的基团被其它氨基酸残基取代; 肿瘤坏死因子抑制剂; 和含有它作为有效成分的肿瘤坏死因子制剂。
摘要:
Disclosed is a novel protein which has a molecular weight of 45,000.+-.5,000 and pI 5.7.+-.0.5 and exhibits cancer metastasis-inhibitory activity. The protein can be prepared by culturing human cells, animal cells and microorganisms capable of producing the protein in a nutrient culture medium while stimulating them with an inducer such as Bacille Calmette-Guerin and lipopolysaccharide.
摘要:
The present invention has the first object to provide a monoclonal antibody specific to interferon α subtype α8 (IFNα8) and its mutant proteins, the second object to provide a hybridoma capable of producing the monoclonal antibody, the third object to provide a method for detecting the IFNα8 and its mutant proteins by the monoclonal antibody, the fourth object to provide a method for purifying the IFNα8 and its mutant proteins by the monoclonal antibody, and the fifth object to provide a therapeutic agent for treating diseases whose onsets or exacerbation are related with IFNα8. The present invention solves the above objects by providing a monoclonal antibody specific to IFNα8 and its mutant proteins, a hybridoma capable of producing the monoclonal antibody, a method for detecting the IFNα8 and its mutant proteins by immunoreaction using the monoclonal antibody, a method for purifying the IFNα8 and its mutant proteins using the monoclonal antibody, and a therapeutic agent for treating diseases whose onsets or exacerbation are related with IFNα8, which contains the monoclonal antibody as an effective ingredient.
摘要:
Disclosed is a novel protein which has a molecular weight of 45,000.+-.5,000 and pI 5.7.+-.0.5 and exhibits cancer metastasis-inhibitory activity. The protein can be prepared by culturing human cells, animal cells and microorganisms capable of producing the protein in a nutrient culture medium while stimulating them with an inducer such as Bacille Calmette-Guerin and lipopolysaccharide.
摘要翻译:公开了一种新型蛋白质,其分子量为45,000 +/- 5,000,pI 5.7 +/- 0.5,具有癌转移抑制活性。 蛋白质可以通过培养能够在营养培养基中产生蛋白质的人细胞,动物细胞和微生物,同时用诸如Baccal Calmette-Gu + E,acu e + EE rin和脂多糖的诱导剂刺激它们来制备。
摘要:
The present invention has an object to provide a novel agent for anti-neurodegenerative diseases and solves the object by providing an agent for anti-neurodegenerative diseases containing, as an effective ingredient, the compound(s) represented by the following General formula 1: wherein in General formula 1, R1 through R3 independently represent a hydrogen atom or an appropriate substituent; Z1 represents a heterocyclic ring and Z2 represents the same or different heterocyclic or aromatic ring as in Z1, wherein the heterocyclic and aromatic rings optionally have a substituent; represents an integer of 0, 1 or 2; p represents an integer of 0 or 1, with the proviso that p is 1 when o is 0 or 2, and p is 0 when o is 1; R1 and R2 do not exist when o is 0, while, when p is 0, R3 does not exist and the binding between the carbon atom to which R2 binds and Z2 is a single bond; X1− represents an appropriate counter anion and q represents an integer of 1 or 2.
摘要翻译:本发明的目的是提供抗神经退行性疾病的新型药剂,通过提供含有下述通式1表示的化合物作为有效成分的抗神经变性疾病试剂来解决本发明的目的:其中 在通式1中,R 1至R 3独立地表示氢原子或适当的取代基; Z1表示杂环,Z2表示与Z1中相同或不同的杂环或芳环,其中杂环和芳环任选具有取代基; 表示0,1或2的整数; p表示0或1的整数,条件是当o为0或2时p为1,当o为1时p为0; 当o为0时,R1和R2不存在,而当p为0时,R3不存在,R2结合的碳原子与Z2为单键的结合; X 1表示适当的抗衡阴离子,q表示1或2的整数。
摘要:
The present invention has an object to provide a tumor necrosis factor mutant protein, particularly, a tumor necrosis factor mutant protein specific to TNF-R1 or TNF-R2; tumor necrosis factor inhibitor; or tumor necrosis factor preparation containing it as an effective ingredient, and the object is solved by providing a tumor necrosis factor mutant protein where one or more amino acid residues selected from the group consisting of 29th, 31st, 32nd, 145th, 146th and 147th, or the group consisting of 84th to 89th from the N-terminal of the amino acid sequence of SEQ ID NO:1 is/are replaced with other amino acid residue(s); a tumor necrosis factor inhibitor; and a tumor necrosis factor preparation containing it as an effective ingredient.
摘要翻译:本发明的目的是提供肿瘤坏死因子突变蛋白,特别是TNF-R1或TNF-R2特异的肿瘤坏死因子突变体蛋白; 肿瘤坏死因子抑制剂; 或含有其作为有效成分的肿瘤坏死因子制剂,其目的是通过提供一种或多种选自第29,31,32,35,146和147位的氨基酸残基的肿瘤坏死因子突变蛋白来解决, 或由SEQ ID NO:1的氨基酸序列的N末端第84位至第89位的基团被其它氨基酸残基取代; 肿瘤坏死因子抑制剂; 和含有它作为有效成分的肿瘤坏死因子制剂。
摘要:
Insertion of IFN-alpha promoters in recombinant DNAs improves their expression efficiencies for useful polypeptides. Expression of such a recombinant DNA in host cells of mammalian origin is artificially controllable by the presence and absence of external stimuli using IFN-alpha inducers. Thus, transformants with such a recombinant DNA readily increase to a maximized cell density with causing neither damages nor extinction due to polypeptides they produce, and subsequent exposure to IFN-alpha inducers allows the proliferated cells to efficiently produce polypeptides with significant glycosylations.